Anteris Technologies reports Q2 2025 net loss $42.7M; cash $28.4M; 130 DurAVR implants

Anteris Technologies Global Corp.

2025-Q2 EPS reported -$1.18 vs consensus -$0.54 ▼ miss (-119.0%)

Revenue from ordinary activities $1.17M for six months, down 16% YoY; net loss $42.7M, up 22% YoY.
130 patients implanted with DurAVR THV since start; 21 in Q2 2025; 79 clinical sites qualified for PARADIGM trial.
R&D expenses $16.3M in Q2 on PARADIGM trial preparation and manufacturing scale-up.
Cash and equivalents $28.4M at June 30, 2025; net operating cash outflow $41.0M in H1 2025.
No dividend declared; board appointed two new directors David Roberts and Gregory Moss.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.